Protalix BioTherapeutics
PLX
PLX
65 hedge funds and large institutions have $6.58M invested in Protalix BioTherapeutics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 12 increasing their positions, 16 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
25% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 16
45% less capital invested
Capital invested by funds: $11.9M → $6.58M (-$5.32M)
Holders
65
Holding in Top 10
–
Calls
$125K
Puts
$5K
Top Buyers
| 1 | +$937K | |
| 2 | +$432K | |
| 3 | +$306K | |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$185K |
| 5 |
CC
Centiva Capital
New York
|
+$152K |
Top Sellers
| 1 | -$3.48M | |
| 2 | -$1.04M | |
| 3 | -$950K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$416K |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
-$342K |